Analytical Data
-
Gene name
NR6A1
- Application
-
Alternative Names
NR6A1; NR6-A1; GCNF1; NR61; RTR; Nuclear Receptor Subfamily 6,Group A,Member 1; Retinoid receptor-related testis-specific receptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q15406
-
Expression Region
Glu282~Glu480
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NR6A1, also known as Nuclear Receptor Subfamily 6, Group A, Member 1, is a crucial transcription factor involved in various biological processes, including embryonic development, metabolism, and cell differentiation. Research surrounding NR6A1 has gained momentum due to its implications in several developmental disorders and diseases. Studies suggest that mutations in the NR6A1 gene can lead to abnormal development and have been linked to conditions such as neurodevelopmental disorders and other syndromic features. As a member of the nuclear receptor superfamily, NR6A1 modulates gene expression in response to various ligands, making it a target of interest for drug discovery and therapeutic interventions. The production of NR6A1 recombinant proteins has become pivotal for understanding its structure-function relationships, interactions with co-regulators, and regulatory mechanisms governing its activity. By generating and characterizing NR6A1 recombinant proteins, researchers aim to elucidate the underlying pathways influenced by this nuclear receptor and explore potential avenues for treatment in NR6A1-associated conditions. Furthermore, studying the recombinant version of NR6A1 allows for high-throughput screening of small molecules that could modulate its activity, providing insights into novel therapeutic strategies. Overall, the research on NR6A1 recombinant proteins holds promise for advancing our understanding of its role in health and disease, paving the way for targeted interventions.
